The farnesoid X receptor (FXR) is a nuclear receptor superfamily member and ligand-activated transcription factor. By binding to DNA as a monomer or a heterodimer with the common NR partner, retinoid x receptor (RXR), to FXR response elements, FXR controls the expression of numerous genes. The FXR and FXR genes are the two recognized FXR genes.
FXR is primarily expressed in the liver and small intestine, where it is critical for the metabolism of bile acids, lipids, and glucose. FXR regulates bile acid (BA) synthesis and homeostasis, glucose and lipid metabolism, as well as playing a significant role in intestinal bacterial growth and liver regeneration through its specific target genes.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V74026 | Alismanol M | 2408810-59-1 | Alismanol M is an agonist of farnesoid X receptor (FXR) with EC50 of 50.25 μM. |
|
V18332 | Cilofexor | 1418274-28-8 | Cilofexor, formerly known as GS-9674, is a farnesoid X receptor (FXR) agonist. |
|
V74025 | Fargesone A | 116424-69-2 | Fargesone A is a potent and specific FXR agonist. |
|
V74032 | FXR antagonist 1 | 2295804-68-9 | FXR antagonist 1 (Compound F6) is an orally bioactive, selective intestinal FXR antagonist (IC50=2.1 μM). |
|
V74028 | FXR antagonist 2 | 1660153-21-8 | FXR antagonist 2 (compound A-26) is a diarylamide analogue, as well as a moderate FXR antagonist. |
|
V78496 | FXRagonist 3 | FXR agonist 3 is an anti-NASH agent that acts by activating FXR. | |
|
V79540 | FXRagonist 4 | FXR agonist 4 (compound 10a) is a farnesoid X receptor (FXR) agonist/activator with EC50 of 1.05 μM. | |
|
V74031 | FXRagonist 5 | 2414008-05-0 | FXR agonist 5 (compound 1) is an FXR agonist. |
|
V29731 | Gly-β-MCA | 66225-78-3 | Gly-β-MCA is a bile acid acting as an oral and potent farnesoid X receptor (FXR) inhibitor with the potential to be usedfor the treatment of metabolic disorders. |
|
V40096 | Glyco-Obeticholic acid | 863239-60-5 | Glyco-Obeticholic acid is an active metabolite of Obeticholic acid formed by a phase II metabolic reaction by conjugating with amino acid glycine. |
|
V79622 | Glyco-obeticholic acid-d5 (obeticholic acid impurity 8-d5) | Glyco-Obeticholic acid-d5 is the deuterated form of Glyco-Obeticholic acid. | |
|
V74024 | HEC96719 | 2181834-03-5 | HEC96719 is a selective and orally bioactive tricyclic farnesoid X receptor (FXR) agonist/activator with EC50s of 1.37 and 1.55 nM via time-resolved fluorescence energy transfer (TR-FRET) and luciferase, respectively. |
|
V74030 | Hedragonic acid | 466-02-4 | Hedragonic acid is an oleanane-type triterpenoid that can be extracted from the stems and roots of Hedragonic acid. |
|
V74027 | Nelumol A | 77836-86-3 | Nelumol A is a farnesoid X receptor (FXR) agonist. |
|
V1844 | Obeticholic Acid (6-ECDCA; INT-747) | 459789-99-2 | Obeticholic Acid (INT747; 6-ECDCA; 6-Ethylchenodeoxycholic acid; trade name Ocaliva), a novel derivative of cholic acid, is a potent,orally bioactive and selectiveagonist of farnesoid X receptor (FXR) with EC50 of 99 nM, and has anticholeretic and anti-inflammatory activities. |
|
V40095 | Tauro-Obeticholic acid | 863239-61-6 | Tauro-Obeticholic acid is an active metabolite of Obeticholic acid(Ocaliva; 6-ECDCA;INT747; 6-Ethylchenodeoxycholic acid) formed by conjugating with taurine, or 2-aminoethanesulfonic acid. |
|
V78711 | Tauro-β-muricholic acid-d4 sodium | Tauro-β-muricholic acid-d4 (sodium) is the deuterated form of Tauro-β-muricholic acid sodium. | |
|
V78572 | XJ02862-S2 | XJ02862-S2 has good FXR agonistic activity. | |
|
V81777 | ZLY28 | ZLY28 is a first-in-class gut-restricted dual modulator of FXR and FABP1 with oral activity. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
